BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:51 PM
 | 
Feb 04, 2010
 |  BC Extra  |  Clinical News

Fidaxomicin meets Phase III endpoint

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) said fidaxomicin ( OPT-80) was non-inferior to Vancocin vancomycin on the primary endpoint of clinical cure rate in the per protocol population (n=451) in a...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >